Eli Lilly is solidifying its leadership in the obesity and diabetes treatment market by implementing significant price cuts for its medications, including a drastic reduction of Mounjaro in China from 2,180 yuan to 445 yuan ($63). The company has also forged new buy points, is considering an acquisition of Abivax, and continues to invest in next-generation obesity therapies, despite a slight share dip of about 0.5%. These strategic moves come as Eli Lilly navigates increasing competition from Novo Nordisk in making effective treatments more accessible.
“Eli Lilly · have forged · new buy points”
“Eli Lilly · have forged · new buy points”
“Eli Lilly · have forged · new buy points”
“Jardiance · is a diabetes treatment from · Eli Lilly and Boehringer Ingelheim”
“Eli Lilly · traded volume · contracts · 15152”
“Eli Lilly · have forged · new buy points”
“Eli Lilly · have forged · new buy points”
“the two biggest drugmakers selling GLP-1s · are · Eli Lilly and Novo Nordisk”
“Eli Lilly · lead in · obesity and diabetes treatment · should hold for years”
“Eli Lilly · holds lead in · obesity and diabetes treatment · for years”
“Eli Lilly · saw shares dip · shares · about 0.5%”
“Eli Lilly · cut prices for · Mounjaro treatment”